select a format

Single User License
USD 2000 INR 130040
Site License
USD 4000 INR 260080
Corporate User License
USD 6000 INR 390120

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Refractory Acute Myeloid Leukemia-Pipeline Review, H2 2015

Refractory Acute Myeloid Leukemia-Pipeline Review, H2 2015


  • Products Id :- GMDHC7212IDB
  • |
  • Pages: 437
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Refractory Acute Myeloid Leukemia-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Refractory Acute Myeloid Leukemia-Pipeline Review, H2 2015', provides an overview of the Refractory Acute Myeloid Leukemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Refractory Acute Myeloid Leukemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Refractory Acute Myeloid Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Refractory Acute Myeloid Leukemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Refractory Acute Myeloid Leukemia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Refractory Acute Myeloid Leukemia Overview 10

Therapeutics Development 11

Pipeline Products for Refractory Acute Myeloid Leukemia-Overview 11

Pipeline Products for Refractory Acute Myeloid Leukemia-Comparative Analysis 12

Refractory Acute Myeloid Leukemia-Therapeutics under Development by Companies 13

Refractory Acute Myeloid Leukemia-Therapeutics under Investigation by Universities/Institutes 18

Refractory Acute Myeloid Leukemia-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Refractory Acute Myeloid Leukemia-Products under Development by Companies 22

Refractory Acute Myeloid Leukemia-Products under Investigation by Universities/Institutes 27

Refractory Acute Myeloid Leukemia-Companies Involved in Therapeutics Development 28

4SC AG 28

AbbVie Inc. 29

Actinium Pharmaceuticals, Inc. 30

Agios Pharmaceuticals, Inc. 31

Amgen Inc. 32

Arog Pharmaceuticals, Inc. 33

Array BioPharma Inc. 34

Astellas Pharma Inc. 35

Astex Pharmaceuticals, Inc. 36

AstraZeneca Plc 37

AVEO Pharmaceuticals, Inc. 38

BioLineRx, Ltd. 39

Boehringer Ingelheim GmbH 40

Boston Biomedical, Inc. 41

Bristol-Myers Squibb Company 42

Calithera Biosciences, Inc. 43

Celgene Corporation 44

Cornerstone Pharmaceuticals, Inc. 45

CTI BioPharma Corp. 46

Daiichi Sankyo Company, Limited 47

Eisai Co., Ltd. 48

EpiZyme, Inc. 49

Exelixis, Inc. 50

F. Hoffmann-La Roche Ltd. 51

FORMA Therapeutics, Inc. 52

Fujifilm Corporation 53

GlaxoSmithKline Plc 54

Igenica Biotherapeutics, Inc. 55

Incyte Corporation 56

Jiangsu Hansoh Pharmaceutical Co., Ltd. 57

JW Pharmaceutical Corporation 58

Karyopharm Therapeutics, Inc. 59

Kyowa Hakko Kirin Co., Ltd. 60

Les Laboratoires Servier SAS 61

MacroGenics, Inc. 62

Merck & Co., Inc. 63

Millennium Pharmaceuticals, Inc. 64

NantKwest, Inc. 65

Novartis AG 66

Otsuka Holdings Co., Ltd. 67

Oxford BioTherapeutics Ltd 68

Pharma Mar, S.A. 69

Polaris Pharmaceuticals, Inc. 70

SpectraMab GmbH 71

Sunesis Pharmaceuticals, Inc. 72

Synta Pharmaceuticals Corp. 73

TaiGen Biotechnology Co., Ltd. 74

Threshold Pharmaceuticals, Inc. 75

Tolero Pharmaceuticals, Inc. 76

Verastem, Inc. 77

Refractory Acute Myeloid Leukemia-Therapeutics Assessment 78

Assessment by Monotherapy Products 78

Assessment by Combination Products 79

Assessment by Target 80

Assessment by Mechanism of Action 85

Assessment by Route of Administration 90

Assessment by Molecule Type 92

Drug Profiles 94

4SC-202-Drug Profile 94

AG-120-Drug Profile 96

alvocidib hydrochloride-Drug Profile 98

AMG-232-Drug Profile 100

AMG-330-Drug Profile 101

aNK Program-Drug Profile 102

AT-9283-Drug Profile 105

BI-836858-Drug Profile 107

binimetinib-Drug Profile 108

BL-8040-Drug Profile 113

bortezomib-Drug Profile 115

buparlisib hydrochloride-Drug Profile 121

burixafor-Drug Profile 125

cabozantinib s-malate-Drug Profile 127

cafusertib hydrochloride-Drug Profile 131

CB-839-Drug Profile 132

CC-90007-Drug Profile 134

Cell Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia-Drug Profile 137

Cell Therapy to Target CD33 for Relapsed and Refractory Acute Myeloid Leukemia-Drug Profile 138

Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies-Drug Profile 139

CPI-613-Drug Profile 140

crenolanib besylate-Drug Profile 143

CWP-291-Drug Profile 145

DFP-10917-Drug Profile 147

DS-3032-Drug Profile 148

E-6201-Drug Profile 149

elesclomol-Drug Profile 151

eltrombopag olamine-Drug Profile 153

erlotinib hydrochloride-Drug Profile 156

evofosfamide-Drug Profile 159

FF-10501-Drug Profile 166

ficlatuzumab-Drug Profile 167

FLX-925-Drug Profile 169

FT-1101-Drug Profile 170

gilteritinib fumarate-Drug Profile 171

GO-2032c-Drug Profile 172

GSK-2879552-Drug Profile 173

GSK-525762-Drug Profile 174

Hu8F4-Drug Profile 175

ibrutinib-Drug Profile 176

IGN-523-Drug Profile 183

ilorasertib-Drug Profile 184

imatinib mesylate-Drug Profile 186

indisulam-Drug Profile 188

Iomab-B-Drug Profile 190

KHK-2823-Drug Profile 192

lenalidomide-Drug Profile 193

lirilumab-Drug Profile 198

lurbinectedin-Drug Profile 200

MGD-006-Drug Profile 203

midostaurin-Drug Profile 204

MK-2206-Drug Profile 206

napabucasin-Drug Profile 209

OPB-51602-Drug Profile 212

Oshadi D + Oshadi R-Drug Profile 213

OX-001-Drug Profile 214

pegargiminase-Drug Profile 215

PIM-447-Drug Profile 219

pinometostat-Drug Profile 220

quizartinib dihydrochloride-Drug Profile 222

RG-7775-Drug Profile 225

ruxolitinib phosphate-Drug Profile 226

S-055746-Drug Profile 231

selinexor-Drug Profile 232

selumetinib sulfate-Drug Profile 238

TAK-659-Drug Profile 242

temozolomide-Drug Profile 243

TEN-010-Drug Profile 245

tigecycline-Drug Profile 246

tosedostat-Drug Profile 247

trametinib dimethyl sulfoxide + uprosertib-Drug Profile 249

Triplebody 19x16x19-Drug Profile 251

ulocuplumab-Drug Profile 252

venetoclax-Drug Profile 254

vorinostat-Drug Profile 257

vosaroxin-Drug Profile 261

VS-4718-Drug Profile 263

Refractory Acute Myeloid Leukemia-Recent Pipeline Updates 264

Refractory Acute Myeloid Leukemia-Dormant Projects 417

Refractory Acute Myeloid Leukemia-Discontinued Products 418

Refractory Acute Myeloid Leukemia-Product Development Milestones 419

Featured News & Press Releases 419

Appendix 430

Methodology 430

Coverage 430

Secondary Research 430

Primary Research 430

Expert Panel Validation 430

Contact Us 430

Disclaimer 431

List of Tables

Number of Products under Development for Refractory Acute Myeloid Leukemia, H2 2015 17

Number of Products under Development for Refractory Acute Myeloid Leukemia-Comparative Analysis, H2 2015 18

Number of Products under Development by Companies, H2 2015 20

Number of Products under Development by Companies, H2 2015 (Contd...1) 21

Number of Products under Development by Companies, H2 2015 (Contd...2) 22

Number of Products under Development by Companies, H2 2015 (Contd...3) 23

Number of Products under Investigation by Universities/Institutes, H2 2015 24

Comparative Analysis by Late Stage Development, H2 2015 25

Comparative Analysis by Clinical Stage Development, H2 2015 26

Comparative Analysis by Early Stage Development, H2 2015 27

Products under Development by Companies, H2 2015 28

Products under Development by Companies, H2 2015 (Contd...1) 29

Products under Development by Companies, H2 2015 (Contd...2) 30

Products under Development by Companies, H2 2015 (Contd...3) 31

Products under Development by Companies, H2 2015 (Contd...4) 32

Products under Investigation by Universities/Institutes, H2 2015 33

Refractory Acute Myeloid Leukemia-Pipeline by 4SC AG, H2 2015 34

Refractory Acute Myeloid Leukemia-Pipeline by AbbVie Inc., H2 2015 35

Refractory Acute Myeloid Leukemia-Pipeline by Actinium Pharmaceuticals, Inc., H2 2015 36

Refractory Acute Myeloid Leukemia-Pipeline by Agios Pharmaceuticals, Inc., H2 2015 37

Refractory Acute Myeloid Leukemia-Pipeline by Amgen Inc., H2 2015 38

Refractory Acute Myeloid Leukemia-Pipeline by Arog Pharmaceuticals, Inc., H2 2015 39

Refractory Acute Myeloid Leukemia-Pipeline by Array BioPharma Inc., H2 2015 40

Refractory Acute Myeloid Leukemia-Pipeline by Astellas Pharma Inc., H2 2015 41

Refractory Acute Myeloid Leukemia-Pipeline by Astex Pharmaceuticals, Inc., H2 2015 42

Refractory Acute Myeloid Leukemia-Pipeline by AstraZeneca Plc, H2 2015 43

Refractory Acute Myeloid Leukemia-Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 44

Refractory Acute Myeloid Leukemia-Pipeline by BioLineRx, Ltd., H2 2015 45

Refractory Acute Myeloid Leukemia-Pipeline by Boehringer Ingelheim GmbH, H2 2015 46

Refractory Acute Myeloid Leukemia-Pipeline by Boston Biomedical, Inc., H2 2015 47

Refractory Acute Myeloid Leukemia-Pipeline by Bristol-Myers Squibb Company, H2 2015 48

Refractory Acute Myeloid Leukemia-Pipeline by Calithera Biosciences, Inc., H2 2015 49

Refractory Acute Myeloid Leukemia-Pipeline by Celgene Corporation, H2 2015 50

Refractory Acute Myeloid Leukemia-Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015 51

Refractory Acute Myeloid Leukemia-Pipeline by CTI BioPharma Corp., H2 2015 52

Refractory Acute Myeloid Leukemia-Pipeline by Daiichi Sankyo Company, Limited, H2 2015 53

Refractory Acute Myeloid Leukemia-Pipeline by Eisai Co., Ltd., H2 2015 54

Refractory Acute Myeloid Leukemia-Pipeline by EpiZyme, Inc., H2 2015 55

Refractory Acute Myeloid Leukemia-Pipeline by Exelixis, Inc., H2 2015 56

Refractory Acute Myeloid Leukemia-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 57

Refractory Acute Myeloid Leukemia-Pipeline by FORMA Therapeutics, Inc., H2 2015 58

Refractory Acute Myeloid Leukemia-Pipeline by Fujifilm Corporation, H2 2015 59

Refractory Acute Myeloid Leukemia-Pipeline by GlaxoSmithKline Plc, H2 2015 60

Refractory Acute Myeloid Leukemia-Pipeline by Igenica Biotherapeutics, Inc., H2 2015 61

Refractory Acute Myeloid Leukemia-Pipeline by Incyte Corporation, H2 2015 62

Refractory Acute Myeloid Leukemia-Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2015 63

Refractory Acute Myeloid Leukemia-Pipeline by JW Pharmaceutical Corporation, H2 2015 64

Refractory Acute Myeloid Leukemia-Pipeline by Karyopharm Therapeutics, Inc., H2 2015 65

Refractory Acute Myeloid Leukemia-Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015 66

Refractory Acute Myeloid Leukemia-Pipeline by Les Laboratoires Servier SAS, H2 2015 67

Refractory Acute Myeloid Leukemia-Pipeline by MacroGenics, Inc., H2 2015 68

Refractory Acute Myeloid Leukemia-Pipeline by Merck & Co., Inc., H2 2015 69

Refractory Acute Myeloid Leukemia-Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 70

Refractory Acute Myeloid Leukemia-Pipeline by NantKwest, Inc., H2 2015 71

Refractory Acute Myeloid Leukemia-Pipeline by Novartis AG, H2 2015 72

Refractory Acute Myeloid Leukemia-Pipeline by Otsuka Holdings Co., Ltd., H2 2015 73

Refractory Acute Myeloid Leukemia-Pipeline by Oxford BioTherapeutics Ltd, H2 2015 74

Refractory Acute Myeloid Leukemia-Pipeline by Pharma Mar, S.A., H2 2015 75

Refractory Acute Myeloid Leukemia-Pipeline by Polaris Pharmaceuticals, Inc., H2 2015 76

Refractory Acute Myeloid Leukemia-Pipeline by SpectraMab GmbH, H2 2015 77

Refractory Acute Myeloid Leukemia-Pipeline by Sunesis Pharmaceuticals, Inc., H2 2015 78

Refractory Acute Myeloid Leukemia-Pipeline by Synta Pharmaceuticals Corp., H2 2015 79

Refractory Acute Myeloid Leukemia-Pipeline by TaiGen Biotechnology Co., Ltd., H2 2015 80

Refractory Acute Myeloid Leukemia-Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 81

Refractory Acute Myeloid Leukemia-Pipeline by Tolero Pharmaceuticals, Inc., H2 2015 82

Refractory Acute Myeloid Leukemia-Pipeline by Verastem, Inc., H2 2015 83

Assessment by Monotherapy Products, H2 2015 84

Assessment by Combination Products, H2 2015 85

Number of Products by Stage and Target, H2 2015 87

Number of Products by Stage and Mechanism of Action, H2 2015 92

Number of Products by Stage and Route of Administration, H2 2015 97

Number of Products by Stage and Molecule Type, H2 2015 99

Refractory Acute Myeloid Leukemia Therapeutics-Recent Pipeline Updates, H2 2015 270

Refractory Acute Myeloid Leukemia-Dormant Projects, H2 2015 423

Refractory Acute Myeloid Leukemia-Discontinued Products, H2 2015 424

List of Figures

Number of Products under Development for Refractory Acute Myeloid Leukemia, H2 2015 17

Number of Products under Development for Refractory Acute Myeloid Leukemia-Comparative Analysis, H2 2015 18

Number of Products under Development by Companies, H2 2015 19

Number of Products under Investigation by Universities/Institutes, H2 2015 24

Comparative Analysis by Clinical Stage Development, H2 2015 26

Comparative Analysis by Early Stage Products, H2 2015 27

Assessment by Monotherapy Products, H2 2015 84

Assessment by Combination Products, H2 2015 85

Number of Products by Top 10 Targets, H2 2015 86

Number of Products by Stage and Top 10 Targets, H2 2015 86

Number of Products by Top 10 Mechanism of Actions, H2 2015 91

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 91

Number of Products by Routes of Administration, H2 2015 96

Number of Products by Stage and Routes of Administration, H2 2015 96

Number of Products by Molecule Types, H2 2015 98

Number of Products by Stage and Molecule Types, H2 2015 98

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

AbbVie Inc.

Actinium Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Amgen Inc.

Arog Pharmaceuticals, Inc.

Array BioPharma Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

BioLineRx, Ltd.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

Celgene Corporation

Cornerstone Pharmaceuticals, Inc.

CTI BioPharma Corp.

Daiichi Sankyo Company, Limited

Eisai Co., Ltd.

EpiZyme, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

FORMA Therapeutics, Inc.

Fujifilm Corporation

GlaxoSmithKline Plc

Igenica Biotherapeutics, Inc.

Incyte Corporation

Jiangsu Hansoh Pharmaceutical Co., Ltd.

JW Pharmaceutical Corporation

Karyopharm Therapeutics, Inc.

Kyowa Hakko Kirin Co., Ltd.

Les Laboratoires Servier SAS

MacroGenics, Inc.

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

NantKwest, Inc.

Novartis AG

Otsuka Holdings Co., Ltd.

Oxford BioTherapeutics Ltd

Pharma Mar, S.A.

Polaris Pharmaceuticals, Inc.

SpectraMab GmbH

Sunesis Pharmaceuticals, Inc.

Synta Pharmaceuticals Corp.

TaiGen Biotechnology Co., Ltd.

Threshold Pharmaceuticals, Inc.

Tolero Pharmaceuticals, Inc.

Verastem, Inc.

Refractory Acute Myeloid Leukemia Therapeutic Products under Development, Key Players in Refractory Acute Myeloid Leukemia Therapeutics, Refractory Acute Myeloid Leukemia Pipeline Overview, Refractory Acute Myeloid Leukemia Pipeline, Refractory Acute Myeloid Leukemia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com